Applied DNA Sciences Files 8-K on Financial Condition
Ticker: BNBX · Form: 8-K · Filed: Feb 8, 2024 · CIK: 744452
Complexity: simple
Sentiment: neutral
Topics: financial-condition, results-of-operations, 8-K
TL;DR
**Applied DNA Sciences just dropped an 8-K on its financials, so check their numbers.**
AI Summary
Applied DNA Sciences, Inc. filed an 8-K on February 8, 2024, to report on its results of operations and financial condition. This filing indicates that the company is providing an update on its financial performance, which is crucial for investors to understand the company's current health and future prospects. For shareholders or potential buyers, this matters because it offers transparency into how the company is managing its finances and whether it is meeting its operational goals, directly impacting stock valuation.
Why It Matters
This filing provides an update on Applied DNA Sciences' financial health, which is essential for investors to assess the company's performance and make informed decisions.
Risk Assessment
Risk Level: medium — The filing itself is a standard disclosure, but the underlying financial condition it reports could carry varying levels of risk depending on the details not provided in this excerpt.
Analyst Insight
Investors should look for the full financial statements and results of operations that this 8-K indicates are forthcoming to understand the company's performance and make informed investment decisions.
Key Numbers
- 001-36745 — Commission File Number (identifies the company's registration with the SEC)
- 59-2262718 — IRS Employer Identification No. (identifies the company for tax purposes)
- 631-240-8800 — Business Phone Number (contact information for the company)
Key Players & Entities
- Applied DNA Sciences, Inc. (company) — the registrant filing the 8-K
- February 8, 2024 (date) — date of earliest event reported and filing date
- Delaware (company) — state of incorporation for Applied DNA Sciences, Inc.
- 001-36745 (dollar_amount) — Commission File Number
- 59-2262718 (dollar_amount) — IRS Employer Identification No.
- 50 Health Sciences Drive Stony Brook, New York 11790 (company) — address of principal executive offices
- 631-240-8800 (dollar_amount) — registrant's telephone number
Forward-Looking Statements
- Applied DNA Sciences will release detailed financial statements soon. (Applied DNA Sciences, Inc.) — high confidence, target: 2024-03-01
FAQ
What is the purpose of this 8-K filing by Applied DNA Sciences, Inc.?
The 8-K filing by Applied DNA Sciences, Inc. on February 8, 2024, is to report on 'Results of Operations and Financial Condition' and 'Financial Statements and Exhibits' as per the ITEM INFORMATION section.
When was the earliest event reported in this 8-K filing?
The date of the earliest event reported in this 8-K filing is February 8, 2024, as stated in the 'Date of Report (Date of earliest event reported)' section.
Where are the principal executive offices of Applied DNA Sciences, Inc. located?
The principal executive offices of Applied DNA Sciences, Inc. are located at 50 Health Sciences Drive, Stony Brook, New York 11790.
What is the Commission File Number for Applied DNA Sciences, Inc.?
The Commission File Number for Applied DNA Sciences, Inc. is 001-36745, as indicated in the filing.
Is Applied DNA Sciences, Inc. an emerging growth company according to this filing?
The filing includes checkboxes for 'emerging growth company' status, but the provided text does not indicate whether the registrant has checked the box, so it cannot be definitively determined from this excerpt.
Filing Stats: 571 words · 2 min read · ~2 pages · Grade level 10.1 · Accepted 2024-02-08 16:05:22
Key Financial Figures
- $0.001 — nge on which registered Common Stock, $0.001 par value APDN The Nasdaq Stock Mar
Filing Documents
- tm245568d1_8k.htm (8-K) — 25KB
- tm245568d1_ex99-1.htm (EX-99.1) — 111KB
- tm245568d1_ex99-1img01.jpg (GRAPHIC) — 25KB
- 0001104659-24-012280.txt ( ) — 352KB
- apdn-20240208.xsd (EX-101.SCH) — 3KB
- apdn-20240208_lab.xml (EX-101.LAB) — 33KB
- apdn-20240208_pre.xml (EX-101.PRE) — 22KB
- tm245568d1_8k_htm.xml (XML) — 3KB
02 Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition. On February 8, 2024, Applied DNA Sciences, Inc. ("Applied DNA Sciences" or the "Company") issued a press release announcing its results of operations for the three-month period ended December 31, 2023. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information furnished pursuant to this Item 2.02, including Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities under that Section and shall not be deemed to be incorporated by reference into any filing of the Company under the Securities Act of 1933 or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. ( d) Exhibits 99.1 Press Release of Applied DNA Sciences, Inc. dated February 8, 2024 regarding results of operations for the three-month period December 31, 2023. 104 Cover Page Interactive Data File (formatted in Inline XBRL) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly author ized. Date: February 8, 2024 APPLIED DNA SCIENCES, INC. By: /s/ James A. Hayward Name: James A. Hayward Title: Chief Executive Officer EXHIBIT INDEX Exhibit No. Description 99.1 Press Release issued by Applied DNA Sciences, Inc. dated February 8, 2024 regarding results of operations for the three-month period ended December 31, 2023. 104 Cover Page Interactive Data File (formatted in Inline XBRL)